ArticleAntimicrobial agents and chemotherapy2020
Candida glabrata Transcription Factor Rpn4 Mediates Fluconazole Resistance through Regulation of Ergosterol Biosynthesis and Plasma Membrane Permeability.
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Aflrpn4 Represents a Promising Target for MitigatingToxins · 2026Article
- Six-month surveillance ofFrontiers in cellular and infection microbiology · 2026Article
- Regulation of Ergosterol Biosynthesis in Pathogenic Fungi: Opportunities for Therapeutic Development.Microorganisms · 2025Review
- Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Proteomic characterization of clinical Candida glabrata isolates with varying degrees of virulence and resistance to fluconazole.PloS one · 2025Article
- The proteasome regulator Rpn4 controls antifungal drug tolerance by coupling protein homeostasis with metabolic responses to drug stress.PLoS pathogens · 2023Article
- Pseudolaric Acid A: A Promising Antifungal Agent Against Prevalent Non-Infection and drug resistance · 2023Article
- Multiple genome analysis ofMicrobial cell (Graz, Austria) · 2022Article
- What 'Omics can tell us about antifungal adaptation.FEMS yeast research · 2022Review
- Characterization of theJournal of fungi (Basel, Switzerland) · 2022Article
- Molecular Mechanisms of Antifungal Resistance in Mucormycosis.BioMed research international · 2022Review
- Copper Acts Synergistically With Fluconazole inFrontiers in microbiology · 2022Article
- Prediction of Gene and Genomic Regulation in Candida Species, Using the PathoYeastract Database: A Comparative Genomics Approach.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Two Sequential Clinical Isolates ofAntibiotics (Basel, Switzerland) · 2021Article
- Article
- Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium.Antibiotics (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability to acquire azole resistance is an emblematic trait of the fungal pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.